Cite
Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
MLA
Schubert, Maria-Luisa, et al. “Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.” Human Gene Therapy, vol. 27, no. 10, Oct. 2016, pp. 758–71. EBSCOhost, https://doi.org/10.1089/hum.2016.097.
APA
Schubert, M.-L., Hückelhoven, A., Hoffmann, J.-M., Schmitt, A., Wuchter, P., Sellner, L., Hofmann, S., Ho, A. D., Dreger, P., & Schmitt, M. (2016). Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. Human Gene Therapy, 27(10), 758–771. https://doi.org/10.1089/hum.2016.097
Chicago
Schubert, Maria-Luisa, Angela Hückelhoven, Jean-Marc Hoffmann, Anita Schmitt, Patrick Wuchter, Leopold Sellner, Susanne Hofmann, Anthony D. Ho, Peter Dreger, and Michael Schmitt. 2016. “Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.” Human Gene Therapy 27 (10): 758–71. doi:10.1089/hum.2016.097.